Skip to main content
Equibles
IART logo

IART · Integra Lifesciences Holdings Corp

Track IART — free

Use IART with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IART.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.40 +0.05 (+0.35%) At close · Nov 13
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.12B
Shares
77.80M
Volume · Nov 13 648.85K Avg daily vol (3M) 1.02M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.40 Open$14.42 Day$14.15–14.62 52W close$8.90–19.85 Avg vol 30d1.2M Short int7.9M · 10.1% of shares · 6.4d Short vol80% Last earningsOct 21, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 23

Up next

Next earnings call
Feb 25, 2027 Est · unconfirmed · in 15 wks
Q3 2026 earnings call transcript
call held Oct 21, 2026
Play latest call

Latest documents

2026
Oct 23
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Integra LifeSciences Holdings Corporation reported $411.2 million in total revenues and $14.9 million in net income for the three months ended September 30, 2026; the Cincinnati flood reduced revenues by approximately $7 million.

Revenue $411.18M ▲ 2.3% Net income $14.85M Diluted EPS $0.19
Read from the MD&A section
Oct 21
Earnings call
Q3 2026 earnings call

Integra Life Sciences posted revenue of $411.2 million and adjusted EPS of $0.59, cut full-year revenue guidance by approximately $30 million due to Cincinnati flooding and tissue reconstruction, and completed a $2.1 billion refinancing.

Oct 21
Current report 8-K
Financial results

Integra LifeSciences reported third-quarter 2026 revenue of $411.2 million, up 2.3%, and adjusted diluted EPS of $0.59; completed a $2.1 billion refinancing; maintained 2026 revenue guidance of $1.634 billion to $1.654 billion and adjusted EPS guidance of $2.30 to $2.40.

Oct 9
Current report 8-K
Regulation FD disclosure

Integra LifeSciences Holdings Corporation priced $450,000,000 aggregate principal amount of 9.500% senior secured notes due 2033, and expects the refinancing to raise its effective interest rate near the high end of the previously communicated 100-200 basis points range.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.66B
Trailing 12 months
Net income (TTM)
$13.01M
Trailing 12 months
Revenue growth YoY
+2.3%
Year over year
Operating margin
4.4%
Trailing 12 months
P / E (TTM)
90.0
Trailing earnings · reciprocal yield 1.1%
FCF yield
7.7%
TTM · current market cap
Return on invested capital
2.9%
Trailing 12 months
Net cash
−$385.57M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.4%
Year over year · more shares
Price change (1Y)
+19.6%
Trailing year
Short interest
10.1%
Latest settlement · 6.4 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲11.5% $442.65M $19.43M '24 Q4* ▲3.7% $382.65M −$25.29M '25 Q1 ▼0.6% $415.61M −$484.07M '25 Q2 ▲5.6% $402.06M −$5.40M '25 Q3 ▼1.7% $434.93M −$1.70M '25 Q4* ▲2.4% $391.92M −$4.62M '26 Q1 ▲0.8% $418.76M $4.48M '26 Q2 LATEST ▲2.3% $411.18M $14.85M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. Integra reported Q2 revenue of $418.8M (+0.8% reported, +0.7% organic) and adjusted EPS of $0.56 above the high end of guidance, driven by tariff favorability and operational execution. The company reaffirmed its full-year organic revenue growth guidance of 0.8%-3.3% and adjusted EPS guidance of $2.40-$2.50, while updating reported revenue outlook for FX and noting an expected Q4 SurgiMend relaunch.

Bullish
  • + Adjusted EPS of $0.56 beat the high end of guidance, up 24% YoY from $0.45
  • + Adjusted EBITDA margin expanded ~160 bps to 18.7% from 17.1%, with adjusted gross margin up ~60 bps to 61.3%
  • + Operating cash flow rose to $22.8M from $8.9M, with leverage down to 4.1x from 4.5x at year-end
  • + Braintree manufacturing restarted, building inventory for Q4 SurgiMend relaunch with PMA label expansion expected in 2027
  • + Specialty Surgery organic revenue grew 1.6%, led by Neurosurgery +1.9% on Certas Plus, CUSA, and Bactiseal
Bearish
  • − Tissue Reconstruction revenue declined 2.0% organically, with Wound Reconstruction down mid-single digits on Integra Skin and MicroMatrix weakness
  • − ENT revenue declined low single digits amid ongoing sinus balloon reimbursement pressure
  • − Higher interest expense from planned refinancing expected in 2H 2026
  • − Reported revenue guidance range lowered to $1.654-$1.695B from $1.662-$1.702B due to stronger USD/FX

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg +1%
above
RSI (14) 54
neutral
MACD trend Positive
52-week position 50%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +9%
trailing
6-month return −5%
trailing
YTD return +16%
this year
Relative strength −6%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $14 › 200d $14 — 50d above 200d
Institutional flow Accumulating
194 of 212 funds reported for Sep 30 · net +1.8M sh shares · +32 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.15% of shares out · ▲ +7.9% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
212 holders — mid 3-yr range
Squeeze score 78
high risk · 0–100
Fundamentals
Weak
Revenue growth +2%
Y/Y
Gross margin 52%
contracting
EPS growth −7389%
Y/Y
Free cash flow $-31.1M
Valuation P/E 90
rich
Buyback $50.0M
remaining
Balance sheet $491.5M
net debt
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −40%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the Earnings Call filed Oct 21, 2026
fourth quarter
Revenue $413M – $433M
prior qtr $411.18M midpoint +2.9% QoQ
Incremental interest expense $8M
full year
Revenue Maintained $1.63B – $1.65B
Oct 2, 2026 $1.63B – $1.65B changed to Oct 21, 2026 $1.63B – $1.65B
prior FY $1.64B midpoint +0.5% Y/Y
Adjusted earnings per share Non-GAAP Maintained $2.30 – $2.40
Oct 2, 2026 $2.30 – $2.40 changed to Oct 21, 2026 $2.30 – $2.40
full-year
Operating cash flow Maintained $190M – $200M
Oct 2, 2026 $190M – $200M changed to Oct 21, 2026 $190M – $200M
2027
Increase in interest expense compared to our updated 2026 outloo $24M
Increase in interest expense $24M
EU MDR spend $2M
Annualization of the transformation work $10M – $15M
Previous outlook earlier release · from the 8-K filed Jul 29, 2026

Still-open targets the latest release did not restate under the same label.

Full-year organic revenue growth · 2026 full-year 0.8% – 3.3%
Prior guidance period ended · from the 8-K filed Oct 2, 2026
Reported revenue · the third quarter ended September 30, 2026 $410M – $412M
Adjusted earnings per diluted share · the third quarter ended September 30, 2026 $0.55 – $0.59
Guided vs delivered · last 8 settled
Revenues third quarter
guided $410M – $425M
$411.18M In line
Total revenue second quarter 2026
guided $410M – $425M
$418.76M In line
Reported revenues first quarter 2026
guided $375M – $390M
$391.92M Beat +2.5%
Revenues full year 2025
guided $1.62B – $1.64B
$1.64B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
+1% Bullish
RSI (14)
54 Neutral
MACD trend
Positive Bullish
52-week position
50% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $14 › 200d $14 — 50d above 200d
Institutional flow Accumulating
194 of 212 funds reported for Sep 30 · net +1.8M sh shares · +32 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.15% of shares out · ▲ +7.9% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
212 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $9 Now $14 · 50% Range high $20
vs 200-day avg +2% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IART
Integra Lifesciences Holdings Corp
this stock
$1.12B +15.9% +1.5% 90.0 10.1%
ABT
Abbott Laboratories
 $187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
 $131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
 $117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
 $64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
231
% held
96.5%
Reported
194 of 212
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
259
View
Short & Settlement
Short Interest Rising
Shares short
7.9M
Days to cover
6.4d
Change
+578.7K sh
View
Short Volume
Short vol %
80%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
2.4K
Value
$33.6K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
35.7%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Josh Gottheimer
Amount
$1.0K–$15.0K
Traded
Jun 18, 2024
View
Financials
Financials
Revenue (FY)
$1.6B
Net income (FY)
$-516.5M
EPS diluted
$-6.74
View
Buybacks
Authorized
$225.0M
Remaining
$50.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 23, 2026
This year
25

Integra LifeSciences Holdings Corporation reported $411.2 million in total revenues and $14.9 million in net income for the three months ended September 30, 2026; the Cincinnati flood reduced revenues by approximately $7 million.

View
Proposed Sales
Value
$100.1K
Shares
4.1K
Filed
Dec 3, 2024
View
Earnings & Events
Webcasts
Last webcast
Oct 21, 2026
View
Investor Relations
Latest news
Integra LifeSciences to Highlight…
Published
Oct 30, 2026
View

Performance

5D 20D 120D MTD YTD
IART +7.3% +9.0% -5.2% +12.9% +15.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +4.7% +10.2% -5.7% +13.1% +5.3%

Capital returns

Buyback program · as of Mar 31, 2026
Authorized
$225.00M
Spent (derived)
$175.00M
Remaining
$50.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 917520 CUSIP 457985208 13F (30d) 188 filings 167 filers Visit website Investor relations